Aug 14, 2020 7:30am EDT Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update
Aug 04, 2020 7:35am EDT Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million
Aug 04, 2020 7:30am EDT Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics
Jul 20, 2020 7:30am EDT Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12
Jul 15, 2020 7:30am EDT Sonnet BioTherapeutics to Present at the 2020 BTIG Virtual Biotechnology Conference
Feb 28, 2020 9:55am EST Sonnet BioTherapeutics to Present at the 40th Annual Cowen Health Care Conference
Oct 22, 2019 9:28am EDT Sonnet BioTherapeutics Selects Abzena as Clinical Stage Manufacturing Partner for its IL-12-FHAB cytokine-derived Therapeutic Candidate
